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This study reviewed community-based direct1y observed treatment (DOT) and the 
conventional approach to tuberculosis management in order to find the most cost­
effective approach. Both patient and health system cost data were used. Hospital cost 
data were collected from a mission hospital in rural Zambia for the periods 1989 and 
1997. Patient cost data were collected from a sample of 50 patients in terms of time and 
travel costs. The cure rate was used as the measure of effectiveness. Results showed that 
community-based DOT is the most cost-effective approach because of its reduced costs 
to the patients and health system. Finally, it was also found that community-based DOT 
is the most viable economic option given the existing resource constraints. Suggestions 
for future study are ofiered and limitations of research are explored. 
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Tuberculosis and Acquired immune deficiency syndrome (AIDS) are probably the most 
baffling but important communicable diseases of this century because of the biology of 
tuberculosis and AIDS, their global impact, diverse modes of transmission, invariable 
fatality and the challenges posed to scientific research and researchers (Saunderson, 
1995). Although both have been widely discussed by the Western media in recent 
decades, for a number of reasons, it is the combination of these two diseases in an ever 
increasing number that is of concern to health planners. While AIDS is untreatable and 
prevention of further infection largely depends on changes in sexual behaviour, 
tuberculosis remains eminently treatable depending on the control strategy of active cases 
and on the drugs used (Saunderson, 1995). 
In recent decades, Zambia has been experiencing an increase in the number of 
tuberculosis cases. While technical advances employed in developed countries have the 
potential to reduce the number of tuberculosis cases reported in Zambia each year, a 
constrained budget prohibits the government from importing such technology. Thus, 
there is need to put to the best use any resources available in the country for what may 
appear to be trivial changes, but which could lead to significant gains in both compliance 
and the cure rates in the management of tuberculosis. This can only be done by using the 
most optimal program design for the control and management of tuberculosis. 
The present study reports on the cost-effectiveness of community-based DOT in a low 
income country. Community based-DOT is compared with conventional care and cost 
data are collected for both the patient and the health system The cure rate is used as the 
measure of effectiveness and cost-effectiveness is determined by the cost per case cured. 
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1.1 Country setting 
Zambia is in central-southern Africa covering an area of 752,610 square kilometres. It is 
a landlocked country and shares common borders with the Democratic Republic of 
Congo, Tanzania, Malawi, Mozambique, Zimbabwe, Namibia and Angola. 
The total population in 1991 was approximately 8 million people of which 55% is found 
in urban areas. The country's growth rate is 3,2 % and the population density is 12 
persons per square kilometre. A total of 48% of the population is under the age of 15 
years. The birth rate in the country is 39,4 births per 1,000 persons; the death rate is 11,4 
deaths per 1,000 persons; and the life expectancy is 59,4 years for males and 65,9 years 
for females. The infant mortality rate is estimated at JOO deaths per 1,000 persons. An 
estimated 65% of the population live within 15 kilometres ofa health facility while 73% 
are within 8 kilometres (Central Statistics Office, 1996). 
Health care in Zambia is provided by government institutions, religious missions, a 
number of parastatal companies, private practitioners, traditional healers and the armed 
services. Of these, the government has been the principal provider of care through a 
wide net work of health centres and hospitals followed by religious missions which 

















The Zambian economy has historically been based on the mining and export of copper. 
Between 1964 and 1975, copper mining and exportation accounted for approximately 
95% of total export earnings. During this period the country's gross domestic product 
(GDP) growth rate was at its prime 8%. However, with the sudden drop in world copper 
prices in 1975, coupled with the early 1980s world recession, the Zambian economy has 
suffered one of the world's steepest and most sudden downturns (World Bank, 1993). 
Thus, in 1990 Zambia dropped from the middle-income category to that of low income. 
The GDP growth rate is currently at -4,5% (Central Statistics Office, 1996). 
1.2 Statement of the problem 
Like other sub-Saharan African countries, Zambia is faced with an increase in the 
number tuberculosis cases spurred on by the HIV/AIDS epidemic. In less than a decade, 
the reported number of cases has risen from 484 in 1989 to weB over 1,000 cases per 
100,000 of the population in 1995 (Central Statistics Office, 1996). This sharp increase 
in the number of cases reported has exerted pressure on the existing health system. 
Occupancy rates in most medical wards have exceeded 100% capacity. In 1994 alone, 
tuberculosis was responsible for more than 30% ofaU hospital admissions and 20% of all 
adult deaths (Central Statistics Office, 1996). 
Prior to 1990, the Zambian government spent more than 20% of its budget on the 
treatment of tuberculosis alone (World Bank, 1993). Given that constrained resources 
preclude the construction of new wards or hiring of additional staff, coping with the 
increase in the case load is proving to be difficult Health institutions have thus, been 
compelled to limit the number of times that a patient can be admitted or discharged 
patients before they are fully ambulant The consequent results have been an increase in 
the number of tuberculosis cases, the development of multi-drug resistant and chronic 
tuberculosis (Zambia Ministry ofHealth, 1997). 
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Community-based DOT is the standard approach to care in the United States and some 
middle income countries (Floyd et.ai, 1997). Though expensive, studies have shown that 
it is less costly than admissions and high cure rates have been achieved (Frieden et.al, 
1995). For instance, Wilkinson and colleagues (1997), observed that the cost of 
managing a patient to treatment completion using community-based DOT in South 
Africa was only R3,156. This compared with an estimated cost of R8,978 for an 
approach which hospitalises patients for two months at the beginning of treatment. In 
addition, they also observed that the DOT approach is effective: 85% of patients 
complete treatment. 
In March 1997, Chikankata mission hospital located in a rural setting in Zambia adopted 
such a program after the observation that (Siankanga, 1990): 
a) 	in rural Zambia the family is the most effective means of supporting the sick 
and of assisting the hospital in providing them with health care and 
psychologicaJ support; 
b) as the incidence of HIVlAIDS continues to grow rapidly, the decentralisation 
of health care is seen to be the only key to providing HIV -infected people with 
medical, nursing, spiritual, social and psychological support; 
c) taking care into the community would in itself have an educational effect on 
members of the family and the wider community. Thus, this would contribute 
to behaviour change and subsequently lead to a reduction in the levels of HIV 
infection in the long-run and; 
d) 	people with incurable illnesses prefer to die at home (AttaweH, 1994). 
Studies on the cost-effectiveness of community-based DOT treatment have been 
conducted in middle income countries in the past (see Barnum, 1986; Murrayet.al, 1991 
and Wilkinson et.al, 1997). The purpose of this study is to evaluate whether community­
based DOT is an attractive economic option in a low income country such as Zambia. 
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The study compares costs to both the patient and the health system under two different 
program designs-community-based DOT and conventional care. 
1.3 Objectives of the study 
The specific objectives of this study are: 
a) to assess whether community-based DOT reduces the cost incurred by the 
health system; 
b) to determine whether community-based DOT reduces the cost incurred by the 
patient and; 
c) to determine the most cost-effective strategy in the management of 
tuberculosis to both the patient and the health system. 
1.4 Justification and significance of the study 
Given the prevailing economic situation of the 1990's, the Zambian government is no 
longer able to support any additional pressure exerted on its health system. More 
seriously, the current practice of many health institutions faced with limited budgets is 
feared to further Jead to an increase in the number of tuberculosis cases. Limiting the 
number of times a patient can be admitted or discharging patients who are not fully 
ambulant so as to visit their nearest health clinic for their DOT may result in the further 
transmission of tuberculosis in the community, the development of multi-drug resistant 
tuberculosis and also the development ofchronic tuberculosis. 
Studies done in both South Africa and Botswana, (two middle income countries) have 
shown that community-based DOT is an economically viable option in a resource 
constrained setting (Floyd, 1997; Murray et.al, 1991). Further, these studies have also 
revealed that community-based DOT can reduce the number of tuberculosis cases and 
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cure over 85% ofcases (Wilkinson eta!, 1997). Whether this option is also economically 
viable and effective in a low income country, faced with limited resources and an 
increase in the number of tuberculosis cases, is to be seen. The study attempts to answer 
the question whether the integration of DOT into the community is the most cost­
effective health intervention available in Zambia. 
The findings of the study may be fed into the policy development plans of the Ministry of 
Health, non-government organisations and other private health sectors in the country in 
their attempt to reduce the number of tuberculosis cases. 
1.5 Organisation of the study 
The remaining chapters of the study are organised as follows: 
Chapter two begins by presenting basic characteristics of tuberculosis. Thereafter, an 
epidemiology of the tuberculosis situation in the country is highlighted. Issues such as 
tuberculosis cases and case rates, age and sex distribution of smear positive tuberculosis, 
hospital morbidity costs, inpatient mortality, types of tuberculosis and measurements of 
its control are presented. 
Chapter three presents a conceptual framework for a cost-effectiveness analysis. A 
summary of the various tools used in economic evaluation with emphasis on cost­
effectiveness analysis is given. The various costs and measures of effectiveness included 
in a cost-effectiveness are also presented. A summary of the methodological issues 
surrounding an economic evaluation are highlighted and finally a critical appraisal of 
studies conducted in South Africa, Botswana and Uganda on the cost-effectiveness of 




















Chapter four presents the methodology used in the study. A description of the setting and 
population sample is presented. The type of cost data collected and measure of 
effectiveness used is outlined. Finally, an outline of the proposed cost and cost­
effectiveness analysis is presented. 
The results in terms of the average health system cost, average patient cost and total costs 
are presented in chapter five. Results of cost-effectiveness and resource use are also 
gIven. 
Chapter six is a discussion of the results in terms of health system costs, patient costs, 
cost-effectiveness and resource use. The likely policy implications of the findings are 

















Characteristics and Epidemiology of Tuberculosis and Measures 
of its Control 
The aim of the chapter is to present the basic characteristics of tuberculosis, its 
epidemiology and measures of its control as applied in Zambia. 
2.1 Basic characteristics of tuberculosis 
The present study defines tuberculosis in agreement with previous studies (e.g. Glatthaar, 
1982; Mclntyre, 1987) as: 
" ... a chronic infectious disease which is caused by specific mycrobacterium and 
is characterised by the formation of lesions in any tissue or organ of the body, but 
mainly in the lungs." 
Using the framework of the above definition, and in line with McIntyre, (1987): 
a) the tubercle bacilli (M Tuberculosis) is transmitted through inhalation and ingestion. 
When a person with infectious tuberculosis coughs or spits, another person who 
inhales the droplets which contains the bacilli is likely to contract the disease. 
b) the tubercle, once transmitted to an uninfected person, causes a 'primary infection' in 
the mid-lung region, and later a 'secondary focus of infection' develops in one of a 
number of possible tissues and organs. In most cases, this occurs in the apices of the 



















c) most people are able to combat the infection with their cellular defence mechanisms 
and develop a natural resistance to further infection. However, in cases where this 
process is not completed, living bacilli may remain in the lesion which can be 
reactivated at a later stage under certain predisposing conditions (McIntyre, 1987, pp. 
20-22). 
2.2 Epidemiology of tuberculosis in Zambia 
This section presents the epidemiology of tuberculosis in Zambia. Definitions of 
common terms used to describe tuberculosis are given. Most of the data presented in this 
section is derived from the Central Statistics Yearly Bulletin, 1996. 
2.2.1 HIV seroprevalence and tuberculosis 
The illV situation in Zambia has had a major impact on the number of tuberculosis cases 
currently being experienced. illV seroprevalence in the country is among the highest 
reported in the sub-Saharan region. Serosurvey results among pregnant women in three 
sites in 1992 showed 38% were HIV positive. A repeat survey in 1993 in seven sites 
showed rates of seropositivity of42,5%. 
Limited data are available on mv seroprevalence among tuberculosis patients. 
However, data from an mv Sentinel Surveillance conducted in 1996, reported that 64% 
ofan reported tuberculosis cases were also infected with mY/AIDs. 
2.2.2 Tuberculosis cases and case rates 
A case of tuberculosis refers to a patient whose disease has been bacteriologically 



















reported in Zambia. Available rates reveal that case rates declined continually until 
1990, when they began to rise. The rate increased from 202/100,000 in 1990 to 
3261100,000 in 1993 which is a 6,1% increase. Tuberculosis case rates in Zambia are 
reported to be amongst the highest in sub-Saharan Africa (Central Statistics Office, 
1996). 
2.2.3 Smear-positive tuberculosis case rates 
Smear-positive refers to tuberculosis cases that are infectious. The more strongly 
positive, the more infectious the patient is said to be. The rate of smear-positive disease 
in 1993 was 6111100,000. There has been considerable variation in the rates of smear­
positive by province in the country, ranging from a low rate of 116/100,000 to a high of 
98211 00,000 during the same year. These differences are due to both local differences in 
disease rates as well as differences in the practice of sputum smears. Smear-positive 
tuberculosis rates in Zambia are also amongst the highest in sub-Saharan Africa (Central 
Statistics Office, ] 996). 
2.2.4 Age and sex distribution of smear-positive cases 
The male to female sex ratio for the period 1987-92 was reported as 1,9:1. The 
distribution of smear-positive cases tends to increase with age with the greatest increase 
in cases experienced between the age group 20-29 years. This age and sex distribution of 
smear-positive cases in Zambia is similar to that experienced in Botswana (Zambia 

















2.2.5 Hospital morbidity and mortality 
In 1986, tuberculosis was the sixth leading cause of inpatient morbidity accounting for 
4,7% of all hospital admissions. In 1991, it was the fifth leading cause accounting for 
4,3% of admissions. During this period, nearly 3 out of 4 patients were hospitalised for 
at least part of the treatment. 
In both 1986 and 1991, tuberculosis was also the leading cause of inpatient mortality, 
accounting for 11,7% and 9,1% of reported inpatient deaths respectively. 
2.2.6 Types of tuberculosis 
The vast majority of tuberculosis cases treated by the Zambia National Tuberculosis 
Program (ZNTP) are pulmonary in nature. In 1992, extra-pulmonary cases accounted for 
10,8% of the total cases. Most ofthe cases reported are new rather than relapse cases. In 
1994, relapses accounted for only 3,7% of all pulmonary cases. 
2.2.7 Sputum analysis among pulmonary cases 
Sputum analysis is a bacteriological investigation used to detect persons infected with 
tuberculosis. The percentage of persons with pulmonary tuberculosis who have had 
sputum examination has increased over the years. In 1996 the percentage of new 
pulmonary tuberculosis patients who had an initial smear investigation was 60% 
















2.2.8 Outcome of treatment 
The outcome of tuberculosis treatment is determined by both the compliance and cure 
rates. The compliance rate is defined as the total number of days attended divided by the 
total number of days that a patient should have attended (Central Statistics Office, 1996). 
Similarly, the cure rate is defmed as the total number of cases cured divided by the total 
number of tuberculosis cases (Central Statistics Office, 1996). 
The overall compliance and cure rates for smear-positive new cases have improved 
markedly over the years. This is largely due to the change in treatment regimens from 
long to short drug regimens. In 1997, compliance rates had increased from 55% in 1989 
to 85%. Likewise, cure rates had improved from 45% to 68% during the same time 
period for the entire country. 
2.3 Measures of tuberculosis control in Zambia 
This section presents the various tuberculosis control strategies used in Zambia. 
2.3.1 Conventional care 
Prior to 1990, treatment of tuberculosis in Zambia was widely based on 2 months of 
inpatient care. This lengthy hospital admission was to ensure patient compliance during 
the most intensive phase when the patient was most infectious. During this period, 














At the time of discharge, the patient was given a one month supply of drugs and 
instructed to subsequently collect drugs once a month from the nearest health clinic for 
the remaining treatment period. The patient was also instructed to collect sputum 
examinations every two months of treatment (2, 4 and 6 months). 
Drug regimens under this approach to care have varied throughout the country. However, 
it is assumed that a six month course was used as recommended by the World Health 
Organisation (WHO). This consists of two months of isoniazid (H), ethambutol (E), 
pyrasinamide (Z) and rifampicin (R), followed by four months ofR and H. 
2.3.2 Directly observed treatment (DOT) 
With the increase in the number of tuberculosis cases reported a revised treatment 
program based on shorter drug regimens and reduced hospital stay was introduced in 
1991 (commonly referred to as short course chemotherapy (SeC». The revised 
treatment program involves 2 months of isoniazid (H), rifampicin (R), pyrasinamide (Z) 
and streptomycin (S) followed by 4 months ofRH. 
The program was directed towards enhancing outpatient care as opposed to inpatient 
care. Thus, it placed emphasis on: immunisation with BCG, case finding and contact 
tracing, case holding and supervision of treatment, health education and community 
mobilisation, and staff training. Some of these components are discussed below. 
2.3.2.1 Immunisation with BGG 
Immunisation with BCG is an integral part of tuberculosis control in Zambia. Children 





















2.3.2.2 Case finding and contact tracing 
Identifying persons infected with tuberculosis is done using various techniques. In 
Zambia, three techniques are commonly used. These are: 
a) chest X-rays - radiological investigation is used extensively as a means ofcase 
finding or contact tracing. Chest X-ray investigations are performed on every 
adult suspected to have tuberculosis. On average a patient may have 4 to 5 X­
rays performed. 
b) bacteriological investigation - adult patients and suspects are asked to produce 
a sputum specimen for laboratory investigations. The sputum undergoes two 
examinations to establish whether tubercle bacilli are present. In the first test­
direct microscopy-a slide of a smear of the sputum is prepared and 
microscopically examined soon after the specimen is obtained. In the second 
test - sputum culture-a culture of the sputum is derived before examination 
(McIntyre, 1987~ p.43). 
c) tuberculin testing - in the screening and diagnosis of tuberculosis in children, 
the Heaftuberculin test This is done by injecting an active ingredient referred 
to as Tuberculin PPD into the epidermis by means of a spring-loaded 'gun'. 
According to the size of the induration, a grading system is used to classify the 
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2.3.2.3 Case holding and supervision of treatment 
The program aims at increasing both the compliance and cure rates. Thus, emphasis is 
placed on direct supervision of at least 6 of the 7 weekly doses. Supervision of treatment 
can be undertaken by a nurse or clinician based in a hospital or health clinic, or by a 
community health worker (CHW) based in the community. 
Patients suspected to have tuberculosis have their diagnosis confirmed by investigating 2 
to 3 sputum samples. Once a case has been confirmed, depending on their clinical 
conditions, patients are asked to remain in hospital for at least 3 three weeks. The 
average length ofstay in hospital in 1997 was 17,5 days. 
While in hospital patients are helped to choose a supervisor who can continue to 
administer treatment after discharge. Emphasis is placed on choosing a supervisor who 
makes accessing of treatment convenient for the patient. 
After discharge, patients are required to take their drugs on an intermittent basis. Thus, a 
patient visits his supervisor twice in a week and 48 times during the entire treatment 
period. 
Supervisors are supervised by a senior doctor and the tuberculosis co-ordinator. Each 
month they make a visit to the patients' supervisor to check on compliance and collect 
outcome data. 
The effectiveness of supervised treatment has been established in previous studies. 
According to Murray et.al (1991), a fully supervised short course treatment achieves 
better results in terms of cure rates and relapse rates than the conventional approach of 















2.3.2.4 Health education 
Health education is aimed at creating greater awareness of the symptoms of tuberculosis 
within the community so as to encourage infected persons to present themselves at a 
clinic for investigation (Mcintyre,1987). Health education is directed towards both 
supervisors and tuberculosis patients. 
2.4 Summary 
In this chapter tuberculosis was defined as a chronic infectious disease caused by a 
specific mycrobacterium. The number of tuberculosis cases reported in the country have 
been increasing over the years spurred on by the AIDSIH1V epidemic. Tuberculosis was 
reported as one of the leading causes of inpatient morbidity and mortality. The age group 
severely infected is between 20-29. 
Prior to 1990, the control and treatment of tuberculosis was largely based on lengthy 
hospital admissions and long drug regimens. With the increase in case loads and low 
patient compliance coupled with low cure rates, a revised treatment regimen based on 
SCC was introduced in 1991. The success of this program is based on full supervision of 
at least 6 of the 7 weekly doses. Supervision of treatment is undertaken by nurses or 






















Conceptual Framework for Cost ..Effectiveness Analysis 
Introduction 
Many times decisions have to be made on how best to use scarce resources within the 
health sector. Health economists use various tools ofeconomic analysis to aid them make 
such decisions. The aim of this chapter is to provide a conceptual framework for the 
evaluation of a health care program. 
3.1 Premise of economic evaluations 
Health economists realise that health producing resources are scarce. Thus, other than 
making decisions based on 'educated guesses', 'gut feelings', and 'what we did last 
time', health economists prefer an organised and systematic consideration of the factors 
involved in a decision to commit resources to one use. One of such consideration is 
conducting an economic evaluation. 
An economic evaluation addresses questions of allocative and technical efficiency. 
Thus, it concerns itself with issues such as whether or not to allocate resource to a given 
program or whether or not to allocate more or less of the available resources. 
There are basically five tools of economic evaluation - namely cost-minimisation 
analysis (CMA), output maximisation analysis (OMA), cost-effectiveness analysis 























3.2 Forms of economic evaluation 
The various tools used in an economic evaluation are presented below. 
3.2.1 Cost and cost-minimisation analysis (CMA) 
A CMA is used when the case for an intervention has been established and the programs 
or procedures under consideration are expected to have the same, or similar, outcomes. 
Given these circumstances, attention is focused on the cost side of the equation to 
identifY the least costly option. 
3.2.2 Cost-benefit analysis (CSA) 
A CBA is the most comprehensive method of economic evaluation which places 
monetary values on both costs and consequences of health care. It is used in cases where 
both costs and consequences of programs or procedures vary, but are expected to have 
the same or similar outcomes. 
CBA can be applied in two ways. The human capital approach means that the value of 
people's contributions is linked to what they are paid. The approach based on 
individual's observed or stated preference means that their personal valuations are placed 
on an activity by assessing how much money they are prepared to accept for an increased 
risk or to pay for a particular service. Each method has its disadvantages. but the most 




i i i l's I">n.o",,...,,,,,,,, r .....,.Y'elU"" 
. ,.. .. ""'''','''''rt











3.2.3 Cost-utility analysis (CUA) 
This approach is also used when costs and consequences of alternatives differ even when 
interventions have the same or similar outcomes. It measures costs in monetary terms and 
consequences in terms of quality adjusted life years (QAL Ys). CUA allows the impact of 
interventions on both mortality and morbidity to be assessed at the same time. 
3.2.4 Output-maximisation analysis (OMA) 
OMA involves identifying the health care option with the highest amount of expected 
output under a given level of resource endowment. Thus, the problem facing a decision 
maker opting to use this tool is: 'Given that the options under evaluation have equal cost, 
which option promises the highest level of output?' 
3.2.5 Cost-effectiveness analysis (CEA) 
CEA involves comparing two or more alternative programs or procedures. Costs are 
measured in monetary terms, while consequences are measured in their natural units. 
This tool of analysis is further discussed below. 
3.3 Cost-effectiveness analysis (CEA) 
The term cost-effectiveness analysis refers to evaluations that measure outcomes of 
alternative programs in natural units. When different health care interventions do not 
produce the same outcomes, the costs and consequences of the options are assessed under 



















compared with outcomes which are measured in their natural units, such as, per life 
saved, per life year gained, per pain or symptom free day or per case cured. 
In order to conduct a cost-effectiveness analysis appropriate measures of costs and 
effectiveness are needed. These will depend on the objectives of the particular 
interventions under review. In most cost-effectiveness analysis, measures of effectiveness 
are defined in appropriate natural units and expressed in a single dimension while the 
costs included are defined by the perspective of the evaluation - such as the societal, 
institutional (health system) and or parental (community) point of view (Drummond and 
Stoddart, 1985). Costs and measures of effectiveness included in a cost-effectiveness 
analysis are discussed below. 
3.3.1 Types of costs 
A cost is defined as any loss of utility or welfare resulting from the project (see McIntyre, 
1987). The choice of cost items included in a cost-effectiveness analysis depends on the 
perspective from which the evaluation is being conducted. If the evaluation is being 
made from the widest perspective viz., the view point of society, then three main 
categories of costs are considered. These are: 
a) 	Organising and operating costs within the health sector: These include clinicians, 
nurses, ancillary staff and support staff time~ administrative time~ materials and 
supplies~ drugs: maintenance of equipment, vehicles and buildings; transport and 
travel; utilities-telephone, postage, water, power; capital costs-plant and 
equipment, vehicles and buildings. 
b) Costs borne by the patients and their families: These include - (i) out of pocket 
expenses e.g. consultation fees, laboratory test fees, x-ray fees, drug fees, other 
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and family inputs into treatment, e.g. special diet expenses, drugs, needles, 
syringes and materials; (iii) time lost from work e.g. production losses, travel 
time, waiting time, consultation time, hospitalisation time and~ (tv) intangible 
costs or psychic: costs, e.g. pain, anxiety and stress. Costs described in (i) and (ii) 
are direct costs, while those in (iii) and (iv) are indirect costs. 
c) External costs: These are costs borne externally to the health sector, patients and 
their famihes as well as other stake-holders e.g. employers, other ministries and 
other people in the neighbourhood whose welfare is affected adversely by the 
presence of the health care intervention. 
3.3.2 Measurement of costs 
Once the range of costs has been identified individual items need to be measured and 
valued. Most direct cost items are valued using market prices based on the notion that, 
where markets are operating perfectly, prices reflect the opportunity cost of the given 
resource (Drummond and Stoddart. 1985). For example, staff time can be valued at the 
appropriate hourly rate and medical supplies can be valued at the prices charged by 
suppliers. 
Capital costs are valued differently since they represent investments at a single point in 
time, often at the begilming of the intervention rather than annual sums. Thus, capital 
costs have two cost components (Drummond and Stoddart, 1985): 
(a) opportunity cost of funds tied up in the capital asset - which can be valued by 
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(b) depreciation costs - which can be measured and valued by annuitizing initial 
capital outlay over the useful life of the assets, i.e., calculating the equivalent 
annual capital cost. 
However, where market rates such as rentals of buildings or lease of equipment exist, 
they may be used to cost capital. 
Indirect costs, on the other hand, for which there are no market prices, are valued using 
'shadow prices'. For example, the time a patient spends in hospital thus, displacing work 
time can be valued using the relevant wage to value lost time. 
3.3.3 Allocation of shared costs 
Shared costs refer to those resources that serve many different programs. These include 
administration and medical record costs. When obtaining cost data for a cost­
effectiveness analysis, such costs need to be allocated appropriately. There are various 
approaches that can be used to do this. However, this study uses the direct allocation 
approach which entails that each overhead cost is allocated directly to final cost centres. 
For example, a programs' allocated share of central administration can be said to be 
equal to central administration cost times that programs proportion of the allocation basis 
which could be paid hours (see Drummond and Stoddart, 1985). The disadvantage of 
allocating costs using this method is that it may lead to an underestimation of costs in all 
final cost centres. 
3.3.5 Measures of effectiveness 
Common measures used in several studies have been 'Jives saved' and 'life years gained' 
(Robinson, 1993). Murray et.aI (1991) in their study ofthe cost-effectiveness ofSCC for 
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tuberculosis treatment in Botswana measured effectiveness in terms of deaths averted 
and years of life saved. 
On the other hand, Floyd et.al (1997) and Saunderson (1995) used the bacteriological 
cure rate as their measure of effectiveness in their studies of the costs and cost­
effectiveness of alternative tuberculosis management strategies in South Africa and 
Uganda respectively. 
Other measures of effectiveness include the compliance and default rates resulting from 
alternative drug regimens in the treatment of tuberculosis (Kumaresan and Maganu. 
1992) and the number of cases successfully treated for tuberculosis after the use of 
alternative drug regimens (Barnum, ] 986). 
3.3.6 Obtaining effectiveness data 
Effectiveness data can be obtained in a number of ways. However, the most ideal is to 
integrate clinical trials into the evaluation in order to collect relevant data on costs and 
effectiveness at the same time (Drummond and Stoddart, 1985). The only problem is 
that setting up and conducting appropriate trials may be time consuming and expensive. 
As a result, many cost-effectiveness analysis rely on the existing medical literature for 
their data. However, if neither specifically designed clinical trials nor the existing work 
provide the necessary data in full, an evaluation may make assumptions about clinical 
evidence (Drummond and Stoddart, 1985). This however, may require that the results 
be subjected to a range of different assumptions about effectiveness through sensitivity 
analysis discussed in detail below. 
Barnum (1986), obtained his effectiveness data by building a clinical trial into his cost­
effectiveness analysis of tuberculosis management in Botswana. Likewise Floyd and 






















study. However, Murray et.al (1991), collected similar effectiveness data from previous 
studies conducted in Malawi, Mozambique and Tanzania. 
3.3.7 Uncertainty and sensitivity analysis 
Sensitivity analysis is a reworking of the analysis using different assumptions on the 
values to be assigned to variables about which there is uncertainty or methodological 
controversy (Drummond and Stoddart, 1985). The objective is to ascertain whether the 
different assumptions have any impact on study results. If the results are sensitive to the 
estimates assumed, further work may be justified to improve the accuracy of estimates. 
This section describes the various sensitivity analysis that can be undertaken. 
3.3.7.1 Risk averse strategy 
The risk averse strategy is used when comparing a new technology with an established 
one. It entails loading the assumptions against the new technology whenever uncertainty 
arises (Warner and Luce, 1982). Given that the new technology emerges as the preferred 
option, even after the assumptions have been staged against it, some confidence can be 
placed in the results (Robinson, 1993). Such an approach was used by Culyer and 
Maynard in their study of the relative cost-effectiveness of surgery versus the then new 
option of cimetidine in the treatment of duodenal ulcers (Culyer and Maynard, 198]). 
Despite the system loading of assumptions in favour of surgery, they concluded that it 
was more cost-effective when the choice was clinically acceptable. 
3.3.7.2 Sensitivity Analysis 
Another approach to uncertainty about the costs effectiveness of different procedures is 


















of the variation in the values of key variables. There are different forms of sensitivity 
analysis (i.e. Briggs et.a1, 1993): 
a) Simple sensitivity analysis entails varying one or more of the components of an 
evaluation to see how it affects the results. For example, Sculpher and colleagues 
varied both the lengths of inpatient stay and the hospital costs per inpatient day in 
their study ofalternative treatments ofmennorrhagia (Sculpher et.al. 1993). 
b) Extreme scenario is another form of sensitivity analysis. Thus, if two treatments 
are being compared this approach would seek to identifY extreme estimates of 
cost and effectiveness so that the two options can be compared under pessimistic 
(high cost and low effectiveness) and optimistic (low cost and high effectiveness) 
assumptions. 
c) Probabilistic sensitivity analysis assigns ranges of distributions to variables, and 
computer programs are used to select values, at random, from each range, and to 
record the results. The advantage of this approach is that it can simultaneously 
deal with a large number of variables and indicate the degree of confidence that 
can be attached to any option. 
By using these different methods of sensitivity analysis it is possible to show whether the 
results of a particular study are accurate over a range of assumptions (Warner and Luce, 
1982). However, many studies do not include sensitivity analysis. According to 
Robinson (1993), an audit conducted by Udvarhelyi et.al (1992). of 77 articles appearing 
in American general medical, general surgical, and medical subspecialty journals over 
two periods 1978-80 and 1985-87 found that, despite the frequent citation of limitations 






















3.4 Limitations of cost·effectiveness analysis 
Cost-effectiveness ana1ysis as a tool of an economic evaluation has limitations. Some of 
these limitations as reported by Drummond and Stoddart (1985) follow: 
a) it cannot resolve the problem of option selection each time different options 
yield more than one kind ofbeneficial effect with the mix of benefits differing 
between options; 
b) it gives no guide as to whether interventions should be implemented at all even 
though it is possible to rank order options to meet a specific objective and; 















3.5 Methodological issues in economic evaluations especially CEA 
Consistent with the present framework, 10 methodological issues of Drummond and 
Stoddart model can be drawn. These are presented in the table below. 
TABLE 1: METHODOLOGICAL ISSUES IN ECONOMIC EVALUATIONS 
1. Was a well...Jefined question posed ill 6. Were costs and consequences valued 
answerable fonn? credibly? 
a) Did the study examine both costs and effects 
of the program( s)1 
b) Did the study involve a comparison of 
alternatives? 
c) Was a viewpoint for the analysis stated? 
2. Was a comprehensive description of the 1 7. Were costs and consequences adjusted for 
competing alternatives given? differential timing? 
3. Was there evidence that the programs' I 8. Was an incremental analysis of costs and 
effectiveness has been established? consequences of alternative perfonned? 
4 . Were all relevant costs and consequences 9. Was a sensitivity analysis perfonned? 
included? 
5 . Were costs and consequences measured 110. Did the presentation and discussion of the 
accurately using in appropriate physical results of the study include all issues of 
units? concern to users? 
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3.5.1 Appraisal of published cost-effectiveness articles 
This section aims at using the Drummond and Stoddart's 10 points criteria to review 
some studies on cost-effectiveness. Articles reviewed were selected because of their 
relevance to the current study, measured in terms of the type of health care interventions 
compared in the studies, the perspectives adopted and similarity in economic 
backgrounds. The articles reviewed are: 
(a) Wilkinson 	etal (1997), a study conducted in Hlabisa South Africa a middle 
income country; 
(b) Saunderson (1995), conducted in Uganda a low income country and;. 
(c) Barnum (1986), conducted in Botswana another middle income country. 
A summarised review of the three studies is presented in Table 2 below. From the table, 
it appears all the three studies have met most of the 10 criteria originally suggested by 
Drummond and Stoddart (1985). The results in each study indicate that the most cost­
effective strategy is that which emphasises outpatient care. It is also clear from the 
conclusions in each study that outpatient care improves both compliance and cure rates. 
From Table 2 below and information on the economic background of each country 
sampled in the studies reviewed, it is revealed that no study has yet been conducted to 
determine the cost-effectiveness of alternative tuberculosis control programs in a low 
income developing country utilising both the health system and patient view points. The 
present study is the first to comprehensively test the validity of the cost-effectiveness of 
alternative tuberculosis management programs in Sub-Saharan Africa as theoretically 




















TABLE 2: A REVIEW OF PREVIOUS COST-EFFECTIVENESS STUDIES 

Wilkinson et.al, (1997) S8W1.derson, (1995) Barnum, (1986) 
Objective(s) (a) Cost-effectiveness 
analysis ofDOT strategy 
and; 












Perspective(s) (a) Health system 
(b) Patient 
Patient view point Health system 
Options (a) DOT 
(b) National strategy 
( c) Sanatorium care 
(a) Inpatient care 
(b) Outpatient care 
(a) Long treatment drug 
regimen (TH); 
(b) Short treatment drug 
regimen (R or E) 
Cost-effectiveness 
measurement 
Cost per case cured Cost per case cured Cost per case cured 
Cost measurement (a) Direct health system and 
patient costs 
(b) Indirect patient costs ­
time lost f om work 
(a) Direct costs - travel 
costs 
(b) Indirect costs - time 
lost from work 
Direct costs incurred by 
the health care system 
Results DOT is the most cost-
effective strategy 
Outpatient care is the 
most cost-effective 
Short term drug regimen is 
most cost-effective 
Conclusion(s) (a) DOT reduces patient and 
health system costs and; 
(b) improves compliance and 
cure rates. 
(a) Outpatient care 
reduces cost to 
patients and; 
(b) improves compliance 
and cure rates 
(a) Short term drug 
regimens reduce 
health system costs 
and', 
(b) 1nlprove compliance 
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The chapter provided a conceptual framework for a cost-effectiveness analysis. Cost­
effectiveness analysis has been described as a fonn of economic evaluation in which the 
costs of alternative procedures or programs are compared with outcomes measured in 
natural units. 
Cost data included in a cost-effectiveness analysis depends on the perspective adopted by 
the study. The widest perspective is the societal view point. Cost items need to be 
valued and measured in their appropriate units. Direct costs are valued using market 
prices, while indirect costs are valued using shadow prices. Capital costs are valued 
using interest or discount rates. 
Effectiveness data are collected from economic evaluations built in alongside clinical 
trials. In the absence of clinical trials, effectiveness data can be obtained from existing 
published work. 
Sensitivity analysis is applied when there is uncertainty about the costs and effectiveness 
of different programs. This analysis investigates the extent to which results are sensitive 
to alternative assumptions about key variables. 
The articles reviewed met most of the methodological issues as defined by Drummond 
and Stoddart (1985). The review of previous cost-effectiveness studies reveals that no 
study has yet been conducted to detennine the cost-effectiveness of alternative 
tuberculosis control programs in a low income countIy especially in Africa, based on 
both patient and health system perspectives. 
-
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This chapter presents the methodology used in this study. These include a description of 
the setting for the study, the type of data sets utilised in the study and their source. The 
size and the criteria of selecting the sample population is also highlighted. 
4.1 Setting 
The study was based at a rural mission hospital run by the Salvation Army of Zambia in 
Chikankata - Mazabuka district. This hospital is situated 130 kilometres south ofLusaka. 
It has a bed capacity of 240 beds and renders services in leprosy, tuberculosis, 
ophthalmology, primary health care (PHC), nutrition and AIDS. It also runs three rural 
health clinics within its catchment area. The hospital serves a population of 
approximately 100,000 which lives within an 80 kilometre radius. The main source of 
income for the people living within the catchment area is peasant farming, teaching in 
surrounding government schools and working as farm labourers. 
The total number of tuberculosis cases reported in the site of study in 1991 was 549, 
representing one of the highest rates in the country. Thirty-five percent of these cases 
were reported between the age group 0-14. The hospital has a tuberculosis co-ordinator 





















The mission hospital was selected as a site of study for the following reasons: 
a) the hospital has the oldest and most successful home-based care programs in 
the country; 
b) the hospital is the only health institution in the country that has in place 
community-based DOT and; 
c) the hospital has a reliable data base. 
4.2 Perspective of the study 
The study adopted a societal viewpoint. Cost data were collected for both the health 
system and the patient. The alternatives reviewed were community-based DOT and 
conventional care. The cost data, effective data, source of data and selection of the 
sample population included in each of the alternatives reviewed are presented below. 
4.3 DOT data collection 
This sub-section gives an overview of the type of data, source of data and the criteria 
utilised in the selection of the study sample. 
4.3.1 Population sample 
A random sample of 50 patients (representing 9,12% of the total number of tuberculosis 
cases reported) was selected from the 1997 tuberculosis register. Age range was 13 
through 76 years. All participants were ethnically Zambians and were randomly matched 

















The participants were not having difficulties with English as a second language. The 
criteria used included: 
a) patients managed on the adult wards (i.e. over 13 years of age), since it is on 
these wards that the problem ofbed capacity exists; 
b) new adult patients diagnosed with all forms of tuberculosis and; 
c) patients who received their DOT within the hospitals' catchment area. 
The locally validated questionnaire used for the study was administered to the 
participants at home in English. The research project had previously been explained to 
the participants. Completion of the self-report instrument was preceded by a thorough 
explanation of the response format, accompanied by a demonstration of several relevant 
examples. 
Hospital records relating to this sample &'TOUp were reviewed and the following 
information was gathered (McIntyre, 1987): 
a) personal details; 

b) process by which tuberculosis was discovered; 

c) results of diagnostic tests; 

d) length of stay in hospital; 

e) treatment regimen; 

f) number of investigations; 

g) compliance to treatment and; 

h) cure rates. 

 

















4.3.2 Data collection for costing 
Cost data were collected for both the hospital and the patient The data included: 
aJ 	Health system costs: Cost data were collected for the entire treatment period. The 
data included - the cost of a day in hospital, a hospital or health clinic visit, sputum 
smear examinations, drugs, administration and, organisation and supervision of 
supervisors. Most of the data were obtained from hospital expenditure records, 
hospital planning and financing units, vehicle logbooks, hospital staff list, hospital 
payroll print-outs, central medical stores and private sector laboratory charges. 
Capital cost data were also obtained by quoting 1997 purchase prices. The expected 
useful life for a vehicle, equipment and buildings were also taken into account and the 
discount rate recorded. 
b) 	Patient costs: Patient costs in terms of travel and time costs were recorded from 
questionnaires administered to a sample of 50 respondents. Time costs were 
translated into monetary costs using monthly incomes reported in the questionnaire. 
4.4 Conventional approach data collection 
For comparison, hospital cost data were obtained for the year 1989 before the 
introduction of DOT. The type of data, source of data and the criteria used in the 















4.4.1 Population sample 
A population sample of 50 patients or participants (representing 15% of the total number 
of tuberculosis cases reported) was selected from the 1989 tuberculosis register. The 
criteria applied in the selection of subjects is similar to that outlined in sub-section 4.3.1. 
Patient folders were searched and information collected were similar to those presented 
in sub-section 4.3.1. 
4.4.2 Data collection for costing 
Cost data were collected only for the health system, which were similar to that presented 
in the sub-section 4.3.2. The sources were used as indicated in the same sub-section. 
4.5 Effectiveness measure 
Since the WHO measure of success is the cure rate, it was used in this study as the 
measure of effectiveness. The cure rates used under conventional care and DOT were 
65% and 85% respectively. Sources of this data included the patients' folder and the 
tuberculosis registers. 
4.6 Cost analysis 
Costs associated with managing tuberculosis patients in each strategy were collected for 
the entire tuberculosis treatment period The actual components of each strategy were 
similar - hospital stay, sputum examination, outpatient or supervisor visits, supervision of 





















whether each component was included in the strategy, the detail of each component (e.g. 
type of drug regimen) and its relative importance (e.g. length ofhospital stay). 
The analysis focused on average costs alone, thereby excluding to calculate any marginal 
costs. According to Wilkinson et.aI (1997) average costs give a better indication of the 
overall cost of a program which allows for a more rigorous comparison than marginal 
costs. 
The average cost of a day in hospital, a hospital visit, a health clinic visit, a visit to the 
CHW, sputum smear, drugs, arrangements for supervision and supervision of supervisors 
and, administration were calculated. Average costs for recurrent items such as x-rays, 
drugs and, sputum tests were calculated using cost data obtained from Central Medical 
Stores. 
Annual capital costs were calculated using quoted 1997 prices. The expected useful life 
years for vehicles, equipment and buildings were assumed to be 5, 10 and 25 years 
respectively. A discount rate of 8% used by the Ministry of Finance for project 
appraisals was used for annualization ofcapital costs. 
Shared costs were allocated using the direct allocation approach. Thus: 
a) 95% of the costs of administrative and support staff and of capital costs were 
allocated to inpatient care and; 
b) 5% to outpatient care since staff involved in direct outpatient accounted for 
5%. 
c) 5% was allocated to laboratory costs since 5% of the total number of 
laboratory tests done in 1997 were tuberculosis investigations. 
In order to calculate the average cost incurred by the patient in terms of travel and time 

















translated into monetary costs using monthly incomes reported in the questionnaire. The 
average monthly income reported was US$113,21. All calculations assumed that patients 
worked 25 days a month and 8 hours a day. Average costs associated with visits to 
hospital and health clinics and for DOT by specific type of supervisory site were 
calculated. 
4.7 Cost-effectiveness analysis 
The cost data was analysed in combination with outcome data to calculate the cost­
effectiveness indicator in tenns of the cost per case treated. This was calculated for both 
the alternatives using the fonnula below (ZMoH, 1997): 
(Average cost per patient X 100) + Cure rate 
A sensitivity analysis was undertaken for those costs about which there was some 
uncertainty regarding their accuracy. 
4.8 Summary 
In order to carry out an economic analysis of the most cost-effective strategy used in the 
control and management of tuberculosis, DOT was compared with conventional care 
using patient and health system cost data. This meant that hospital cost data were 
collected for two different time periods, Le.: 
(a) for the period 1989 just before the introduction ofooT an¢ 
(b) for the period 1997 after the introduction ofooT. 
Hospital cost data collected included drug costs, administration costs, laboratory test 




















number of documents such as patient folders, payroll printouts, vehicle logbooks, and 
other hospital records. Patient cost data collected included time and travel costs. These 
were obtained by analysing questionnaires completed by a population sample of 50 
respondents. 
Cost data under each strategy were manipulated to calculate average costs for the health 
system and patient. In order to determine the most cost-effective strategy, cost data were 















This chapter presents the results. All cost data presented are converted to US$ (dollar) 
using the conversion rate US$1 1,325 Zambian Kwacha (ZK). 
5.1 Average health system, patient and total costs 
Calculations of the average health system costs, patient costs and total costs, showed that 
DOT is considerably cheaper than the conventional strategy. From TabJe 3 below, it is 
2,6 times cheaper for the health system, 2,5 times cheaper for the patient and 2,6 times 
cheaper overall. In both cases, health system costs accounted for 92% oftotal costs. 
It is also clear that admission to hospital is the most costly item. For DOT, it accounted 
for 72,6% of health system costs, 67% of patient costs and 73% of costs overall; for the 
conventional approach, it accounted for 92,2% of health system costs, 93,2% of patient 
costs and 92,2% of costs overall The other important cost items were visits for DOT 
(13,2% of the total cost of the DOT strategy) and drugs (7,3% of the total cost of the 
directly observed treatment strategy). Arrangements for supervision and supervision of 
supervisors seemed to be relatively inexpensive, accounting for only 4,6% of the total 
















TABLE 3: AVERAGE HEALTH SYSTEM, PATIENT AND TOTAL COSTS IN 1997 US$ (PERCENTAGE OF TOTAL) FOR CURING ONE 
PATIENT WITH TUBERCULOSIS ACCORDING TO MANAGEMENT. 
Health system costs Patient costs Total costs 









Hospital stay 439,59 (73%) 1479,74(92,2%) 37,98(67%) 130.2(93,2%) 477,57(72,6%) 1609,94(92,2%) 
Visits fOf DOT 79,2(13,2%) N/A 18,72(33%) N/A 97,2(14,8%) N/A 
Outpatient visits for sputum 
collection 
N/A 31,38(2%) N/A 5,4(4%) N/A 36,78(2,1%) 
Health clinic visits for 
collection ofpills 
N/A 27,83(1,7%) N/A 4,05(2,8%) N/A 31,88(1,8%) 
Arrangements for supervision 
and supervision ofSUperviSOfS 30,13(5%) N/A N/A N/A 30,13(4,6%) N/A 
Drugs 48(8%) 54(3,31%) N/A N/A 48(7,3%) 54(3,1%) 
Sputum examinations N/A 7,5(0,47%) N/A N/A N/A 7,5(0,4%) 
Management and audit 5,14(0,8%) 5,14(0,32%) N/A N/A 5,14(0,7%) 5,14(0,3%) 














5.2 Average health system costs 
The average health system costs are presented in Table 4 below. 
TABLE 4: AVERAGE HEALTH SYSTEM COSTS IN 1997 US$ 
Cost Item Average Cost 
Day in hospital (excluding drugs and laboratory tests) 24,66 
Outpatient visits (excluding drugs and laboratory tests) 13,96 
Health clinic visits (excluding drugs and laboratory tests) 5,23 
VisittoCHW 0 
Visit for DOT 1,65 
Course of drug treatment: 
• DOT 
• Conventionally delivered treatment 
48 
54 
Arrangements for supervision and supervision ofsupervisors 30,13 
Management and audit 5,14 
Sputum smear testing 1,25 
The most expensive item for the health system is drugs. However, differences in the cost 
of the drug regimens used were not large (between US$48 for the DOT regimen and 
US$54 for conventionally delivered treatment). The likely explanation for the high drug 
cost is the use ofstreptomycin in the treatment oftuberculosis in its early stages. 
A sensitivity analysis performed on the cost of the different drug regimens showed no 




















Supervision plays a pivotal role in tuberculosis management under community-based 
DOT. According the Table 4, the organisation of supervision and the supervision of 
supervisors were less than expected at US$30,14 per patient. The average cost ofa day in 
hospital is US$24,66. Given that inpatient care at the mission hospital is very basic with 
food being provided by relatives of the patient, the cost reported is high. Also, the figure 
represents a minimal level of nursing supervision since much of the basic nursing care is 
done by relatives of the patient. Thus, if food was to be provided and the costs of full 
nursing supervision taken into account, this item of cost would be much higher. 
Although the cost of drugs and laboratory investigations were omitted, average costs 
incurred by the health system in terms of outpatient visits for collection of sputum and 
monthly collection of piUs are costly at US$J3,96. On the other hand, the average cost of 
health clinic visits for the monthly collection of pills is US$5,23. 
Each visit for DOT cost the health system an average sum ofUS$1,55. In calculating this 
cost, it was assumed that 46% of the patients were supervised by staff in health clinics, 
27% by CHWs and, another 27% by staff in the tuberculosis ward. This is according to 
1997 data. The average cost of management and audit was US$5, 14. The least average 
cost estimated was US$1,65 for sputum smear testing. Visits to CHW by patients cost 
the health system US$O,OO because CHWs supervise treatment on a voluntary basis. 
5.3 Average patie t costs 
The data for average patient costs calculated in terms of time and travel costs are 
presented in Table 5 below. Diagnosis and treatment of tuberculosis is free to the 
patient. However. most patients incur personal costs for transport and from lost income. 
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TABLE 5: AVERAGE PATIENT COSTS IN 1997 US$ 
Cost Item Travel Cost Time Cos!Jeq~ivaJen: in mhlu~e~t ... Total Cost ..., 
Day in hospital ° 3,79(480) 3,79 
Hospital visit 0,82 5,13(540) 5,95 
Health clinic visit 0,126 1,22(129) 1,35 
Visit for directly observed treatment: 
• when TB ward chosen: 0,35 0,70(122) 1,05 
• when health clinic chosen: ° 0,45(78) 0,45 
• when community health worker chosen ° 0,14(15) 0,14 
• Average ~ 0,2 0,2(20) 0,39 
t It was assumed that 25 out of30 days were worked. Thus, a day in hospital is equivalent to 8 working hours or, 480 minutes. The average income 

per month of 50 inpatients with tuberculosis was estimated at US$ 113,21. 

: In calculating this cost, it was assumed that 46% of the patients were supervised by staff in health clinics, 27% by community health workers and, 
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A short questionnaire designed to identifY the patients costs was completed for 50 
tuberculosis patients who were found to be smear positive. The respondents comprised of 
20 males and 30 females. The questionnaire was used to establish the time and travel 
costs associated with visits to the hospital, health clinics and CHWs. Patients were asked 
about the time it takes to access care and the travel costs involved. 
Their median age was 35 years (range was 15 to 76). The average number of dependants 
was 6. Analysis of the questionnaire showed that 35% of the patients were subsistence 
farmers, 16% were farm labourers, 13% were teachers and other professions, 13% were 
self-employed, 9% were in school and, 27% were either Wlemployed or housewives. 
From Table 5, it is apparent that the total average patient cost for a hospital visit is the 
most significant at US$5,95. On the other hand, a visit to the a CHW did not require any 
travel expenditures; the small Joss to the patient is a r flection of the time lost from 
income generating activity. Visits to clinics and particularly hospital are more expensive 
because travel costs rise as time lost from work increases. 
A day in hospital cost the patient US$3,79. In calculating this cost, it was assumed that 
25 out of 30 days were worked. Thus, an average day in hospital is equivalent to 8 
working hours or, 480 minutes. The average monthly income reported by the respondents 
was US$l13, 21. 
Visits for DOT to the tuberculosis ward, health clinic and CHWs cost a total ofUS$l,05, 
US$0,45 and US$0,14 respectively. The least costly visit was to the CHWs. It was also 
the only cost below the given average cost of US$0,39. In terms of time, a hospital visit 
cost a patient 2 hours, a health clinic visit 1,3 hours and a visit to CHWs 15 minutes. 
Once again, it is clear that a visit to a CHW in tenns of time cost the patient less. This 



















5.4 Cost-effectiveness data 
Table 6 below. gives details ofhow DOT utilises resources. It is apparent from the table 
that DOT is the most efficient. At US$863,79 per patient cured, it is 4 times more cost­
effective than the conventional approach. 
5.5 Resource use data 
Table 7 shows that DOT is also feasible within existing resource constraints. The reduced 
length of stay under community-based DOT means that it can be implemented without 
displacing patients from other wards, reducing the quality of care provided, and needing 
extra investment in both infrastructure and staff 
5.6 Summary 
The study results show that community-based DOT is far much more cost-effective than 
the conventional approach. In combination, arrangements for supervision, supervision of 
supervisors, and 48 visits cost the health system US$109,33 per patient which is 
equivalent to 4,4 days spent in hospital receiving treatment for tuberculosis. It cost the 
patient US$18,7 which is equivalent to 5 days in hospital. Further, the total cost of 
supervising a patient under community-based care is less than expected. Although there 
were small variations in cost items under each strategy, these were overweighed by the 
agreement that DOT is most cost-effective. 
The results also show that community-based DOT reduces the amount of pressure 
exerted on the existing bed capacity. Therefore, it is a viable and feasible option that can 
be implemented using existing resources. 
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TABLE 6: COST-EFFECTIVENESS OF DIFFERENT CASE MANAGEMENT STRATEGIES 

Management strategy Cost for a cured 
patient ($)(% of 
patients) 
Cost for a patient who 
completes treatment 
but for whom cure is 
not confirmed ($)(% of 
patients) 
Cost for a patient who does 
not complete treatment 










2555,70(65) 2555,70(0) 1806,47(35) 
.­ - -­ --­ ._---------------­ ---- -­
65 3931,85 
TABLE 7: NUMBERS OF BEDS AVAILABLE AND REQUIRED TO MANAGE PATIENTS WITH TUBERCULOSIS 

Number of beds required given: 
Management strategy Number of beds 
available 
1995 case 1996 case 1997 case 




DOT (average length of stay 17,5 days) 40 19,44 30,67 28 20 
Conventionally delivered treatment (av. length of 
stay 60 days) 
40 66,66 105,16 98 69 
I 
* Includes 1$1 quarter only 
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Discussion and Conclusion 
Introduction 
The aim of this chapter is to present a discussion of the fmdings in the study. An attempt 
is made to make comparisons with results of previous cost-effectiveness studies 
conducted in Africa. Limitations of the study are also outlined in this chapter and 
conclusions given. 
6.1 Discussion 
A discussion of the study results is presented below. 
6.1.1 Average health system costs 
The overall results of this study indicate that average costs incurred by the health system 
under the community-based DOT strategy are less than those reported under the 
conventional approach to care. The main reason for this low cost is the short period of 
hospitalisation. Treatment under community-based DOT is based in the community and 
supervised by community health workers who work on a voluntary basis. This makes it 
cheaper than lengthy hospital supervision and care. All other components of the cost of 
tuberculosis management under community-based DOT are relatively small when 
















The study also found that the average cost incurred by the health system in the 
supervision of community-based DOT is not significantly high. This is an important 
finding because supervision plays a pivotal role in determining the success of 
community-based DOT. Instead, on the contrary, the results seem to indicate that shifting 
the emphasis of care from the hospital to the community significantly reduces health 
system average costs. For example, the cost of arrangements for supervision and 
supervision of supervisors (US$30,13) in combination with 48 visits by the patient 
(US$79,20) is US$109,33. This is equivalent to only 4,4 days in hospital. 
As Wilkinson et.al (1997) noted, the cost of hospital care is unlikely to fall enough to 
make DOT comparatively expensive even in a very poor setting. In support of their 
argument, they cite an example of Malawi where the cost of a day in hospital was 
US$2,09 in 1995. Thus, 60 days in hospital cost the health system US$125,40, while 
community-based DOT - 48 visits for DOT and CHW supervision - cost only US$64,30. 
This calculation assumed that health clinic and CHW visits and driver costs were 13,3 
times less than those reported in HIabisa - the site of study. 
6.1.2 Average patient costs 
The results also indicate that community-based DOT reduces the amount of travel and 
time costs incurred by patients by allowing an easy access to care for the patient and by 
reducing the length of stay in hospital by a patient. In this study, it was calculated that 
the reduced length of stay in hospital saves the patient as much as US$161, 08, assuming 
that a day in hospital costs the patient US$3,79. 
Further, additional savings are achieved by the patient when a CHW is visited for DOT as 
opposed to a clinic or hospital visit It was found that a visit to a CHW did not result in 
any travel cost due to the close proximity of the CHW. Whatever cost is indicated 



















clinics (US$0,45) and the hospital (US$1,05) cost more because of the rise in travel costs 
and an increase in the time lost from work. 
6.1.3 Cost-effectiveness analysis 
The cost-effectiveness fmdings of this study are similar to findings in other studies 
conducted in the same area. The results show that community-based DOT is three times 
far much more cost-effective than conventional care. According to available statistics, 
cure rates have reportedly increased from 65% in 1989 to 85% in 1997. Similarly, the 
cost of treating a patient for the entire treatment period is US$820,60 as opposed to 
US$2,555.70 under conventional care. The improved effectiveness and reduced costs are 
indicators of the positive achievements that have been brought about by the adoption of 
community-based DOT 
These findings are in line with Floyd et.al (1997), who carried out a study on the cost­
effectiveness of alternative tuberculosis management strategies in Hlabisa, South Africa 
and observed that community-based DOT was 28 times more cost-effective than 
conventional care. In addition, they observed that after DOT was introduced cure rates 
increased from a 17% in 1990 to 81% between 1991 and 1994 and the cost of curing a 
patient had fallen from R88,307 to R3,799. 
A study by Saunderson (1995) also revealed that community-based DOT was far much 
more efficient than conventional care in Uganda. Not only had the introduction of 
community-based DOT reduced the costs incurred by the health system and the patient in 
the region under study, but also higher compliance and cure rates were reported 

















6.1.4 Resource use analysis 
The findings also show that community-based DOT utilises resources more efficiently. 
Compared to the conventional approach, shorter hospitalisation of patients means that 
patients are not displaced from other wards, quality ofcare is not compromised with, and 
extra investment in both infrastructure and staff is not needed. Thus, implementing 
community-based DOT in Zambia should significantly help to decongest hospitals, 
thereby improving the hospitals' capacity to cope with the growing tuberculosis case 
load. The findings of the present study lend credence to the fact that more resources 
should be directed towards Primary Health Care (PHC) and outpatient Care. 
6.1.5 Application of study results to other districts in Zambia 
Similar findings can be expected in other districts in Zambia, provided that the cost of 
major inputs such as staff, vehicles and fuel and population densities do not vary much 
from those included in this study. As with all scientific endeavour, replication of several 
study of this nature in Africa is needed to confirm or disconfirm these fmdings. 
6.1.6 Policy implications 
From the study it is clear that a simplified approach to tuberculosis management based on 
short hospital stay and a strong community program is most cost-effective. Thus, health 
care resources should be directed towards PHC programs and outpatient care. Further, 
resources need to be directed towards the training ofCHWs who playa critical role in the 














6.2 Limitations of study and directions for future research 
The 1imitations of the study were: 
a) the costs of the patients were based on a small sample without a control group. 
Therefore, further studies are needed to confirm these tentative findings; 
b) the study focused solely on new tuberculosis cases, thus, omitting important 
information that might have been found in re-treatment cases and; 
c) the sample group included in the study was adult tuberculosis patients only. 
In terms of the survey's utility, the results of the present study may serve several 
purposes. First, this information can serve as an important springboard for the successful 
integration of proven PHC with community-based DOT in sub-Saharan Africa. Second, 
this data can also play an instrumental role in assessing the feasibility of implementing 
community-based DOT interventions. In this regard, the degree of similarity between 
these results obtained here and those reported for previous studies reviewed was 
encouragmg. Finally, research of this type may yield useful data that could serve as a 
guide to future research. Future research could also investigate whether the frequency of 
community-based DOT practices is reflective of available resources and the socio­
economic status in the target country. The results obtained here tentatively suggest it 
might. 
6.3 Conclusion 
In sum, the present fmdings provided tentative support for community-based DOT and 
PHC as well as for the validity of Drummond and Stoddart's to-points. Clearly, the 
model requires suitable adoption and further development. To a greater extent, 
community-based DOT in the present study has shown to significantly reduce costs to 
















both the health system and patient. The study has also shown that community-based DOT 
is implementable within the existing infrastructure. This makes community-based DOT 
an attractive and viable economic option that should be implemented in a country faced 
with constrained resources and a limited budget. Continued implementation of 
community-based DOT in other parts of Zambia is a likely solution to coping with the 
increased tuberculosis case load. Taken together, community-based DOT in developed 
and developing countries (especially low-income countries) should have considerable 
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b 	 If yes, what type of employment? 
1 = student 2 domestic worker 
3 = shop assistant 4 = labourer (i.e. construction, mining, factory, 
transportation) 

5 = fann worker 6 = office worker/professional 

7 = other (please specify)-------------------------------------------------- ­
c 	 What is your average income per month? 
1 < K150,OOO 2 = K150,OOO - K300,OOO 
3 ~ K300,OOO - K500,OOO 4 = >K500,OOO 
3 	 If employed, are you entitled to sick leave? 
1 yes 2 no 
b 	 If yes, is it paid or unpaid? 
1 = paid 2 unpaid 
4 	 If unemployed what is your source of income? 
1 terminal benefits 2 = support from family/friends 
3 = none 	 4 other (please specify )---------------------------­
Health status 
How many days did you spend in hospital?-------------------------------------------­
2a 	 How did you return home after being discharged from hospital? 
1 = walked 2 private transport 
3 public transport 4 = other (please specify )--------------------------­
b 	 If you did not walk, how much did you spend on transport? 
1 = <Kl,OOO 2 Kl,OOO-K3,OOO 
3 K3,OOO - K5,OOO 4 = >K5,OOO 
5 I don't know 
c 	 How many minutes did it take you to arrive home from hospital? 
1 = <30minutes 2 30minutes - 45minutes 
3 = 45minutes - 60minutes 4 60minutes - 90minutes 
5 = > 90minutes 6 = I don't know 
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3a 	 Is your answer to 3( a) your usual mode of transport? 
1 = yes 2 no 
b 	 If no, what is your usual mode of transport? 
] = walking 2 = private transport 
3 = public transport 4 other (please specify )---------------- ­
c 	 If no, how many minutes would it take you to arrive home using your usual mode 
of transport? 
] <30minutes 2 = 30minutes - 45minutes 
3 45minutes - 60minutes 4 60minutes - 90minutes 
5 = > 90minutes 6 I don't know 
4a 	 Who supervises your treatment? 
1 = staff in TB ward at the hospital 
2 health clinic staff 
3 = community health workers 
4 = other (please specify)---------------------------------------------- ­
5a 	 How far is your supervisor from your house? 
1 <lOkm 2 JOkm - 25km 
3 = 25km - 50km 4 = >50km 
5 = I don't know 
b 	 How do you get to your supervisor? 
1 walked 2 private transport 
3 = public transport 4 other (please specify )---------------------- ­
c 	 If you do not walk, how much do you spend on transport? 
1 <Kl,OOO 2 KI,OOO - K3,OOO 
3 = K3,OOO - K5,OOO 4 >K5,OOO 
5 = I don't know 
d 	 How many minutes does it take you to get to your supervisor? 
1 <30minutes 2 = 30minutes - 45minutes 
3 = 45minutes - 60minutes 4 60minutes - 90minutes 
5 = > 90minutes 6 I don't know 
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